论文部分内容阅读
目的:探讨肝病及发热患者附红体感染状况及临床治疗疗效。方法:按照统一的调查表进行问卷调查,采集患者外周血检测附红体,将确诊为附红体感染的279例患者随机分为阿米卡星组、依替米星组、盐酸左氧氟沙星组三组,并分别观察其疗效。结果:调查1 693例,附红体感染279例,阳性率为16.48%,均为轻度感染。阿米卡星组、依替米星组、左氧氟沙星组三组治疗有效率分别为83.87%、93.55%、96.77%,左氧氟沙星组疗效优于阿米卡星组。结论:肝病及发热患者附红体感染为轻度感染,与一般人群感染率接近,左氧氟沙星治疗附红体感染疗效好。
Objective: To investigate the status of infection of red body in patients with liver disease and fever and the clinical curative effect. Methods: A questionnaire was conducted according to a unified questionnaire. Peripheral blood samples were collected from patients with red body. 279 patients diagnosed with red body infection were randomly divided into amikacin group, eptifibatide group and levofloxacin hydrochloride group three Group, and observe their curative effect respectively. Results: A total of 1 693 cases were investigated. 279 cases were infected with red body. The positive rate was 16.48%, all of which were mild infection. The effective rates of amikacin group, etimicin group and levofloxacin group were 83.87%, 93.55% and 96.77% respectively. The efficacy of levofloxacin group was better than amikacin group. Conclusion: The infection of red body with liver disease and febrile disease is mild infection, and the infection rate with the general population is close. Levofloxacin treatment with red body infection is effective.